jueves, 5 de noviembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 20, 2026

Live Nation signals double-digit AOI growth in 2026 while expanding global venue footprint

View original at seekingalpha.com
Live Nation signals double-digit AOI growth in 2026 while expanding global venue footprint Earnings Call Insights: Live Nation Entertainment (LYV) Q4 2025 MANAGEMENT VIEW * Michael Rapino, President, CEO & Director, indicated that the business continues its global expansion, highlighting sustained growth across all ven…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The business continues its global expansion with sustained growth across all venue segments and geographies

    80% confidence

  • Sponsorship expected to continue to be up double digits in 2026, with over 70% booked and running double digits ahead

    80% confidence

  • Company optimistic it can maintain staying ahead of 2024 and 2025 performance in 2026

    80% confidence

  • Live entertainment is a continual growth industry on a global basis with high single digits industry-wide growth, and Live Nation expects to beat that

    80% confidence

  • Fan count contributions in owner/operated venues were 20% from venues opened in '25, about 1/3 from venues opened in '26, and about half organic

    80% confidence

  • Equal appetite for live entertainment across global markets

    80% confidence

  • Sell-through rates are consistent with last year, with record demand for some top artists

    80% confidence

  • Venue management acquisitions are not a core strategy

    80% confidence

  • Concerts projected to achieve double-digit solid growth in 2026

    80% confidence

  • Recent DOJ ruling diminished the breakup of the company argument

    80% confidence

  • Arenas up double digits in show count and stadiums up double digits for 2026, particularly driven by international markets

    80% confidence

  • Venue Nation incurred $25 million cost in prior year, ramping up to $50 million in current year due to preopening expenses

    80% confidence

  • No pullback or any issues whatsoever in demand for budget conscious fans

    80% confidence

  • Ticketmaster's gross transaction value grew about 6%, driven by 9% increase in concerts with 1% decline in sports and other third party

    80% confidence

  • DOJ determination that promotion and booking services are not a monopoly is a critical element that takes away edge risk

    80% confidence

  • Global arena investments are hitting benchmarks and supporting broader continental goals

    80% confidence

  • Venues choose Ticketmaster because we just sell more tickets, with technology and marketing tools as key reasons

    80% confidence

  • Ticketing expected to show underlying mid-single-digit growth but with some onetime headwinds on secondary market

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,549 documentos fuente archivados
Consulta estos datos → isubstrate.com
Live Nation signals double-digit AOI growth in 2026 while expanding global venue footprint — Source | Via News | es.VIA.NEWS